Healthcare, Pharma & Life Sciences

Philadelphia – November 03, 2026 -- Signant Health has launched SignalSpace, a connected environment that combines its applications, study activity, support, workflows, data and AI-guided intelligence in one secure destination for sites, sponsors and CROs. SignalSpace comes standard with Signant solutions.

The product targets fragmentation in trial technology. A single study often involves multiple systems, logins, workflows and support channels, which makes uninterrupted work and data access harder. SignalSpace gives site teams one starting point so they can move between Signant solutions without losing context. Sponsors and CROs get a broader view across studies, products and programs.

San Antonio – November 03, 2026 -- Frost & Sullivan has named A&D Medical its 2026 Global Company of the Year in home monitoring technologies, citing product innovation, clinical accuracy and connected care delivery.

Cellular blood pressure monitor removes smartphone and Wi-Fi requirements

The Cellular Blood Pressure Monitor (UA-1020CEL) transmits readings automatically through built-in cellular connectivity. Patients need no smartphone, mobile app or Wi-Fi connection. Frost & Sullivan says this lowers technology barriers for certain patient populations and gives providers a simpler way to support more diverse patient groups.

The device captures three consecutive readings through programmable averaging and calculates an averaged result that aligns with clinical guidelines, according to Frost & Sullivan Industry Analyst Utkarsha Soundankar. It also includes irregular heartbeat detection to support remote patient monitoring.

St. Louis – November 03, 2026 -- The American College of Lifestyle Medicine (ACLM) and eClinicalWorks are embedding six lifestyle medicine tools in eClinicalWorks EHR 12.0.4, moving assessment, documentation, patient education and outcomes tracking into clinicians' existing workflows.

Six tools cover assessment through outcomes reporting

The Lifestyle Medicine Whole Person Health Assessment evaluates patients across nutrition, physical activity, restorative sleep, stress management, connectedness and avoidance of risky substances. A progress note template lets clinicians document prescribed interventions and patient goals, including food-as-medicine measures such as produce prescriptions and medically tailored groceries and meals.

ALLENTOWN – November 03, 2026 -- JULABO USA Chief Financial Officer Sam Wolf has been selected as a 2026 Leaders in Business & Finance honoree by Lehigh Valley Business in the Chief Financial Officer/VP of Finance category, months after the company reported its highest-performing quarter to date.

Wolf took the CFO role in May 2026 and helped deliver the company's best quarter

Wolf was promoted to CFO in May 2026. Since then, he has played a key role in JULABO USA's financial performance and long-term growth, including the highest-performing quarter in the company's history, according to the announcement. He joined JULABO USA during the economic uncertainty of the COVID-19 pandemic.

SAN DIEGO – November 02, 2026 -- Neurocrine Biosciences (Nasdaq: NBIX) grew third-quarter 2026 revenue 41% year over year to $1.1 billion, up from $795 million, and raised its full-year INGREZZA net sales guidance to $2.9 billion to $2.925 billion.

The prior INGREZZA range was $2.825 billion to $2.875 billion. Net product sales topped $1 billion for the first time, according to the company.

INGREZZA sales rise 17% to $801 million on double-digit volume growth

INGREZZA growth reflected record TRx and NRx and high persistency rates. CRENESSITY contributed $211 million, with approximately 80% reimbursement for dispensed prescriptions. VYKAT XR added $107 million.

Neurocrine acquired VYKAT XR through its purchase of Soleno Therapeutics, which closed in May 2026. The company recorded about $2.2 billion of VYKAT XR intellectual property on its balance sheet, to be amortized over an expected 16 years.

Menlo Park – November 02, 2026 -- Hippocratic AI has launched Polaris 6 Ultra, a healthcare language model that runs a 7.4-trillion-parameter safety constellation 1.3 times faster end to end than its predecessor, Polaris 5, as patients experience it.

The company says the model is the first in healthcare to read a patient's emotional state and plan its next sentence while the previous one is still being spoken. Polaris 5 ran at 5.0 trillion parameters.

Polaris 6 Ultra reaches the first sentence in 0.28 seconds against 0.71 to 0.94 for rivals

On byte-identical prompts on a 671B-parameter LLM, Hippocratic AI's serving stack reaches the first sentence in 0.28 seconds. The four fastest commercial providers took 0.71 to 0.94 seconds. Time to first sentence for the LLM stays at 278 milliseconds.

STOCKHOLM – November 02, 2026 -- BioArctic AB will keep the full USD 30 million upfront payment from Novartis Pharma AG after Novartis terminated their Option, Collaboration and License Agreement, the Nasdaq Stockholm-listed company (BIOA B) announced.

Novartis drops the program, not the technology

The agreement was signed in August 2025. It covered a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Novartis proprietary antibody. Novartis notified BioArctic that it decided to discontinue the program. According to BioArctic, the decision is unrelated to the BrainTransporter technology.

BioArctic books the remaining upfront payment as 2026 revenue

Because of the termination, BioArctic will recognize the remaining unrecognized portion of the USD 30 million upfront payment as revenue in 2026. The company did not disclose the size of that portion.

MIAMI – November 02, 2026 -- Brand and condition websites account for just 17% of AI-answer citations on average, according to PharmaForceIQ audits behind the launch of Share of Answer, a new module in its Optichannel 360 platform for biopharma companies.

Audits find retired webpages and superseded FDA labeling in AI answers

The audits identified citations to hundreds of retired webpages. In one analysis, AI-generated responses quoted superseded FDA-approved labeling in nearly 250 answers.

Abbreviations also caused errors. In a rare disease analysis, AI engines identified the condition correctly when prompted with its full name, but more than half of the answers failed to identify it when an abbreviation was used.

TAMPA, Fla. – November 02, 2026 -- Tampa General Hospital (TGH) ranks No. 3 in Florida and No. 1 on Florida's West Coast in Newsweek's 2027 America's Best-in-State Hospitals ranking, the fourth consecutive year it has been the highest-ranked hospital in the Tampa Bay region.

TGH has held the regional top spot every year since the list began. It has also placed among Florida's top three hospitals in every edition.

Newsweek and Statista rank 800 hospitals across four data sources

Newsweek compiled the list with Statista. Hospitals from all U.S. states were eligible and included in a nationwide survey. Each was scored on hospital quality metrics, hospital reputation, patient experience and a Statista Patient-Reported Outcome Measures (PROMs) implementation survey.

Singapore – November 02, 2026 -- Ultima Genomics' UG200 Sequencing Platform has been selected for the SG-INSIGHT cohort of Phase III of Singapore's National Precision Medicine (NPM) program, which will cover about 450,000 individuals. The company calls it its first major win supporting a national-scale clinical whole genome sequencing initiative. Financial terms were not disclosed.

Phase III targets nearly one in 10 Singapore residents

NPM Phase III is about 4.5 times the size of Phase II, which sequenced 100,000 Singaporeans. The new phase also shifts from healthy individuals to patients across a wide spectrum of health conditions. Participants will come from Singapore's three public healthcare clusters: NHG Health, National University Health System (NUHS) and SingHealth.